CHANG NANCY T 4

4 · Immix Biopharma, Inc. · Filed May 29, 2026

AI-generated summary of this filing

Updated May 29, 2026

Immix Biopharma (IMMX) Director Nancy T. Chang Receives Equity Awards

What Happened

Nancy T. Chang, a director of Immix Biopharma (IMMX), received two equity awards on May 22, 2026: 6,250 restricted stock units (RSUs) and rights to 12,500 derivative shares (a stock‑based award). Both were granted at $0.00, so no cash was paid. These are compensation awards (not open‑market purchases or sales).

Key Details

Transaction date: May 22, 2026; Filing date: May 29, 2026 (filed after the typical two‑business‑day Form 4 window).
6,250 RSUs granted at $0.00. Vesting: vests in full on the earlier of (i) one year after grant or (ii) the issuer's 2027 annual meeting, subject to continued service (Footnote F1).
12,500 derivative award (stock option/right) granted at $0.00. Vesting: generally vests in substantially equal monthly installments over 12 months, with any remaining unvested portion vesting if the 2027 annual meeting occurs before the one‑year anniversary, subject to continued board service (Footnote F3).
Shares owned after the transaction: not specified in the provided Form 4 data.
Beneficial‑ownership note: Chang is general manager of Robinhood II, LP and may be deemed to beneficially own securities held by that entity, but she disclaims beneficial ownership except to the extent of her pecuniary interest (Footnote F2).
Remarks: Exhibit 24.1 (Powers of Attorney) included on the filing.

Context

These awards are typical director compensation and represent future potential equity if vesting conditions are met; they are not sales or purchases indicating immediate market action. RSUs convert to shares at vesting; the derivative award will vest over time and would require exercise/settlement steps before Chang holds shares outright. The Form 4 was filed days after the transaction, which is later than the usual two‑business‑day requirement.

Form 4

Period: 2026-05-22

Director

Transactions

Award
Common Stock
[F1]
2026-05-22+6,250→ 428,190 total
Award
Stock Option (Right to Buy)
[F3]
2026-05-22+12,500→ 12,500 total
Exercise: $8.78Exp: 2036-05-22→ Common Stock (12,500 underlying)

Holdings

Footnotes (3)

[F1]The Reporting Person was granted 6,250 restricted stock units ("RSUs") pursuant to the Issuer's 2021 Equity Incentive Plan, which RSUs will vest in full on the earlier of (i) the one-year anniversary of the date of grant, and (ii) the date that the Issuer's 2027 annual meeting of stockholders (the "2027 Annual Meeting") is held, subject to the Reporting Person's continued service with the Issuer.
[F2]The Reporting Person is the general manager of Robinhood II, LP and may be deemed to beneficially own the securities held by Robinhood II, LP. The Reporting Person disclaims beneficial ownership of the common stock owned directly by Robinhood II, LP, except to the extent of her pecuniary interest therein.
[F3]The stock option will vest in substantially equal monthly installments over the 12 months following the date of grant (or, in the event the 2027 Annual Meeting occurs prior to the first anniversary of the date of grant, any remaining unvested portion of the stock option will vest on the date of such 2027 Annual Meeting), subject to the Reporting Person's continued service on the Issuer's Board through the applicable vesting date.

Signature

/s/ Ilya Rachman as Attorney-In-Fact for Nancy T. Chang|2026-05-29

2 files